Iantrek, Inc. has officially launched AlloFlo Uveo, a bio-interventional surgical implant for glaucoma, to the U.S. commercial market.
Hold up … didn’t we just hear about this device?
We did—in August. But that wasn’t necessarily a product update so much as a funding one that enabled this commercial launch.
Specifically: Iantrek raised $42 million in a Series C financing round (see here for those details).
Gotcha. So, where to start?
With the product itself, of course.
What it is: AlloFlo Uveo is a “first-of-its-kind” surgical device that targets the uveoscleral pathway during minimally-invasive glaucoma surgery (MIGS).
Its purpose: The device is designed for high precision, ab-interno homologous structural reinforcement, providing ophthalmic surgeons an alternative route for draining fluids from the eye.
- How: Via a porous, biologic material that both adheres and reinforces specific channels around the cornea’s edge—all without damage to the conjunctiva or the use of metal / synthetic hardware.
Go on ..
Another important component of this is the AlloSert Uveo.
Why: Because while AlloFlo is a bio-tissue implant (dual bio-spacers) that reinforces a cyclodialysis cleft and supports uveoscleral outflow, it’s actually dependent on the AlloSert Uveo.
- What this is: A delivery platform (or spacer delivery system) that creates the controlled cyclodialysis and positions the AlloFlo spacers (which then ensure long-term uveoscleral drainage reinforcement).
- Check out these instructions for the process (as well as contraindications and warnings for use).
So, how does AlloFlo Uveo compare to existing MIGS devices?
One major distinction worth calling out: It targets the uveoscleral pathway, unlike other MIGS devices, which target the conventional trabecular outflow route.
Why this makes a difference: The resulting impact could potentially offer “dual-flow potential” involving both the trabecular and uveoscleral pathways (and, thus, be more effective in its intraocular pressure [IOP]-lowering capabilities).
Noted. So, what has clinical research found?
Promising data, as evidenced by recent peer-reviewed research on the bio-reinforced implant’s long-term (2-year) efficacy and safety in lowering IOP among glaucoma patients post-cataract surgery.
- Check out the gist of those findings.
Plus: On a more real-world clinical evidence front: Over 3,000 procedures using the AlloFlo Uveo have been performed by ophthalmic surgeons across the country (as part of an early access program).
Impressive. And the significance?
Iantrek CEO Adam Szaronos noted that the AlloFlo Uveo technology’s U.S. launch “represents the arrival of a new minimally-invasive and complementary category in glaucoma surgery.”
We’re expanding our commercial organization to support the growing number of surgeons eager to get started with AlloFlo Uveo, ensuring they have the resources and partnership needed for success.
Lastly, when and where will this be more widely available?
Good question.
If you’re attending the 2025 American Academy of Ophthalmology (AAO) annual meeting this weekend (Oct. 18-20), Iantrek will be showcasing the device at its booth (#3501).
Otherwise, reach out to the company for more details.